1	Genomic Landscape of Lymphatic Malformations: A Case Series and Response
2	to the PI3K α Inhibitor Alpelisib in an N-of-One Clinical Trial
3	Montaser F. Shaheen ^{1,2,*,†} , Julie Y. Tse ^{3,*,†} , Ethan S. Sokol ³ , Margaret Masterson ^{4,5} ,
4	Pranshu Bansal ^{6,7} , Ian Rabinowitz ^{6,7} , Christy A. Tarleton ^{6,8} , Andrey S. Dobroff ^{6,8} , Tracey
5	L. Smith ^{9,10} , Thèrése J. Bocklage ^{6,11} , Brian K. Mannakee ^{1,12} , Ryan N. Gutenkunst ^{1,13} ,
6	Joyce E. Bischoff ^{14,15} , Scott A. Ness ^{6,8} , Gregory M. Riedlinger ^{4,16} , Roman Groisberg ^{4,17} ,
7	Renata Pasqualini ^{9,10,†} , Shridar Ganesan ^{4,17,*,‡} , and Wadih Arap ^{6,18,*,‡}
8	¹ University of Arizona Cancer Center; Tucson, AZ 85719.
9	² Division of Hematology/Oncology, Department of Medicine, University of Arizona College of
10	Medicine; Tucson, AZ 85724.
11	³ Foundation Medicine, Inc.; Cambridge, MA 02141.
12	⁴ Rutgers Cancer Institute of New Jersey; New Brunswick, NJ 08901.
13 14	⁵ Department of Pediatrics, Rutgers Robert Wood Johnson Medical School; New Brunswick, NJ 08901.
15	⁶ University of New Mexico Comprehensive Cancer Center; Albuquerque, NM 87131.
16 17	⁷ Division of Hematology/Oncology, Department of Internal Medicine, University of New Mexico School of Medicine: Albuquerque, NM 87131.
19	⁸ Division of Molocular Modicing, Dopartment of Internal Modicing, University of New Maxico
19	School of Medicine; Albuquerque, NM 87131.
20	⁹ Rutgers Cancer Institute of New Jersey; Newark, NJ 07103.
21 22	¹⁰ Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School; Newark, NJ 07103.

- ²³ ¹¹Department of Pathology, University of Kentucky College of Medicine and Markey Cancer
- 24 Center; Lexington, KY 40536.
- ²⁵ ¹²Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public
- Health, University of Arizona; Tucson, AZ 85724.
- ¹³Department of Molecular and Cellular Biology, College of Science, University of Arizona;
- 28 Tucson, AZ 85721.
- ¹⁴Vascular Biology Program, Boston Children's Hospital; Boston, MA 02115.
- ¹⁵Department of Surgery, Harvard Medical School; Boston, MA 02115.
- ¹⁶Department of Pathology, Rutgers Robert Wood Johnson Medical School; New Brunswick, NJ
 08901.
- ¹⁷Division of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson
- 34 Medical School; New Brunswick, NJ 08901.
- ¹⁸Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical
- 36 School, Newark, NJ 07103.
- ³⁷ *Corresponding authors. Correspondence should be addressed to Dr. Wadih Arap, 185 South
- 38 Orange Ave. B-1121, Newark, NJ 07103, phone: 973-972-0366, E-mail:
- 39 <u>wadih.arap@rutgers.edu;</u> Dr. Montaser F. Shaheen, E-mail: <u>shaheenm@email.arizona.edu;</u> Dr.
- 40 Julie Y. Tse, E-mail: jtse@foundationmedicine.com; or Dr. Shridar Ganesan, E-mail:
- 41 ganesash@cinj.rutgers.edu.
- ⁴² [†]Montaser F. Shaheen and Julie Y. Tse contributed equally to this work.
- ⁴³ [‡]Renata Pasqualini, Shridar Ganesan, and Wadih Arap jointly supervised this work.
- 44
- 45 Conflict of interest statement: M.F.S. reports personal fees from Illumina, BMS, and Qiagen
- 46 (outside of the submitted work). J.Y.T., E.S.S., and B.K.M. are employees of Foundation
- 47 Medicine, Inc., a wholly owned subsidiary of Roche, and they own equity in Roche. S.G. has
- 48 consulting agreements with Merck, Roche, Novartis, Foundation Medicine, EQRX, Foghorn

49	Therapeutics, Silagene, and KayoThera and owns equity in Silagene; his spouse is an
50	employee of Merck and owns equity in Merck (all outside of the submitted work). R.G. reports
51	research funding/grant support for clinical trials (to his institution) from Regeneron, BMS,
52	Merck/EMD Serano, Amgen, Roche/Genentech, Philogen; consulting/advisory board fees from
53	Regeneron; and speaker fees for Deciphera (all outside of the submitted work). R.P. and W.A.
54	are founders and equity stockholders of PhageNova Bio and of MBrace Therapeutics; R.P. is a
55	paid consultant for PhageNova Bio and MBrace Therapeutics and also serves as the Chief
56	Scientific Officer of PhageNova Bio and a member of the board for MBrace Therapeutics (all
57	outside of the submitted work). For R.G., R.P., S.G., and W.A., these arrangements are
58	managed in accordance with the established institutional conflict of interest policies of Rutgers,
59	The State University of New Jersey. The remaining authors have declared no potential
60	competing interests.
61	
62	
63	KEYWORDS: lymphatic malformations, genomics, NGS, PI3K α

64

66 **ABSTRACT**

67 **Background:** Lymphatic malformations (LMs) often pose treatment challenges due to a large

size or a critical location that could lead to disfigurement, and there are no standardized

69 treatment approaches for either refractory or unresectable cases.

- 70 Methods: We examined the genomic landscape of a patient cohort of LMs (n=30 cases) that
- ⁷¹ underwent comprehensive genomic profiling (CGP) using a large-panel next generation

⁷² sequencing (NGS) assay. Immunohistochemical analyses were completed in parallel.

73 Results: These LMs had low mutational burden with hotspot PIK3CA mutations and NRAS

74 mutations being most frequent, and mutually exclusive. All LM cases with Kaposi sarcoma-like

75 (kaposiform) histology had *NRAS* mutations. One index patient presented with subacute

abdominal pain and was diagnosed with a large retroperitoneal lymphatic malformation

harboring a somatic *PIK3CA* gain-of-function mutation (H1047R). The patient achieved a rapid

and durable complete response to the PI3K α inhibitor alpelisib within the context of a

79 personalized N-of-1 clinical trial (NCT03941782). In translational correlative studies, canonical

80 PI3Kα pathway activation was confirmed by immunohistochemistry and human LM-derived

81 lymphatic endothelial cells carrying an allele with an activating mutation at the same locus were

82 sensitive *in vitro* to alpelisib in a concentration-dependent manner.

Conclusions: Our findings establish that LM patients with conventional or kaposiform histology
 have distinct, yet targetable, driver mutations.

Funding: R.P. and W.A. are supported by awards from the Levy-Longenbaugh Fund. S.G. is supported by awards from the Hugs for Brady Foundation. This work has been funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the University of Arizona Cancer Center (CA023074), the University of New Mexico Comprehensive Cancer Center (CA118100), and the

- 89 Rutgers Cancer Institute of New Jersey (CA072720). B.K.M. was supported by National Science
- 90 Foundation via Graduate Research Fellowship DGE-1143953.
- 91 Clinical trial number: NCT03941782
- 92
- 93
- 94

95 INTRODUCTION

Vascular anomalies, including lymphatic malformations (LMs), are usually diagnosed in children 96 97 or young individuals and they can present as either isolated lesions or as part of somatic or congenital syndromes. In general, LMs are managed by sclerotherapy, laser, or surgical 98 interventions when there is an indication for therapy¹. In certain cases, LMs can attain large 99 sizes or involve critical locations, which poses treatment challenges such as the possibility of 100 101 disfigurement. Genomic sequencing has demonstrated a somatic clonal origin for a number of 102 non-malignant growth conditions including LMs. Activating PIK3CA mutations have been reported in most pediatric patients with isolated or syndromic LMs². This finding has led to the 103 104 use of mammalian target of rapamycin (mTOR) inhibitors for systemic therapy of unresectable LMs, given that mTOR is a molecule downstream of the PI3K pathway³. However, only a 105 subset of patients responded, and the treatment can have substantial side-effects. PI3K 106 inhibitors have also been reported as being effective in treatment of children with diseases in 107 108 the PIK3CA-related Overgrowth Spectrum (termed PROS), but the efficacy of alpelisib in 109 isolated sporadic LMs is not at all clear. Similarly, it is not as yet clear which oncogenic drivers, if any, are present in LMs with wild-type PIK3CA alleles. 110

111

To define the spectrum of genomic alterations and lesions present in LMs, here we have
analyzed a patient cohort of LMs (n=30 cases) assayed by clinical-grade genomic sequencing.
Pathogenic activating mutations in *PIK3CA* and *NRAS* were the most common genetic
alterations found. Strikingly, the *PIK3CA* and *NRAS* mutations were mutually exclusive with *NRAS* mutations being greatly enriched in LMs with kaposiform morphology. We have also
performed an N-of-1 trial of the PI3Kα inhibitor alpelisib in a young man with an activating *PIK3CA* point mutation, presenting with a giant (unresectable) retroperitoneal and pancreatic

- LM, who had a dramatic and prolonged response to the drug lasting years, and we present
- 120 confirmatory translational correlates *in vitro*.
- 121

122 123 **RESULTS**

124 Mutational Landscape and Histopathology of Lymphatic Malformations

A set of thirty cases of LMs (from 30 individual patients) were assayed with genomic profiling at 125 126 Foundation Medicine, Inc. (Cambridge, MA). Twenty-eight cases were sequenced using hybrid-127 capture next-generation sequencing (NGS) targeting exons of 300+ cancer genes and select 128 introns of 36 genes. Two other cases were sequenced using hybrid-capture based DNA sequencing targeting exons of 406+ cancer genes and select introns of 36 genes, plus RNA 129 sequencing of 265 genes for rearrangement calling. The patients were predominantly pediatric 130 131 age (median 9-year-old; range, 1-year-old to 45-years-old), with a slight female predominance (17 females, 57% to 13 males, 43%). Seven patients had a documented history of prior 132 treatment with an mTOR inhibitor, such as sirolimus. Seven patients (23%) carried clinical 133 diagnoses of overgrowth syndromes including Congenital Lipomatous Overgrowth with 134 135 Vascular, Epidermal, and Skeletal anomalies (termed CLOVES), Klippel-Trenaunay Syndrome, and PTEN-like hamartoma syndrome. Twelve patients (40%) had multifocal disease and eight 136 patients had involvement of bone and visceral sites (Table 1). Expert histopathological review 137 showed that only four (13%) had kaposiform morphology, while 26 (87%) had conventional 138 139 histology. The estimated histopathologic purity ranged from 10% to 70% (median 20%).

- 140
- 141
- 142
- 143
- 144

145	Table 1	: Clinical and	histological	features of I	ym	phatic ma	Iformation of	col
-----	---------	----------------	--------------	---------------	----	-----------	---------------	-----

Table 1	: Clinica	al and	l histologi	cal featur	es of lymp	hatic malf	ormation co	ohort	
Patient	Age range (years)	Sex	Clinical syndrome	Localized vs. multifocal	Location of LM(s)	Specimen type	LM histology	PIK3CA or NRAS alteration	% VAF
1	6-10	М	CLOVES	Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> E542K	14
2	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	PIK3CA E542K	7
3	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK</i> 3CA H1047R	11
4	16-20	М		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK</i> 3CA H1047R	4
5	16-20	М		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK</i> 3CA H1047L	4
6	6-10	F	Klippel- Trenaunay	Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	9
7	6-10	М		Localized	Visceral	Core biopsy	Conventional	PIK3CA E545K	7
8	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	PIK3CA C420R	5
9	21-25	М		Localized	Visceral	Incisional biopsy	Conventional	<i>PIK</i> 3CA H1047R	4
10	16-20	F	PTEN-like hamartoma	Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	3
11	0-5	F	CLOVES	Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> E545K	12
12	0-5	М		Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	2
13	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	PIK3CA E542K	6
14	0-5	М		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047R	5
15	0-5	F		Localized	Superficial soft tissues	Excision	Conventional	PIK3CA E545K	1
16	11-15	F		Multifocal	Visceral	Excision	Conventional	PIK3CA C420R	14
17	0-5	F	CLOVES	Multifocal	Superficial soft tissues	Excision	Conventional	PIK3CA C420R	38
18	16-20	F	CLOVES	Localized	Superficial soft tissues	Excision	Conventional	PIK3CA E453K	32
19	6-10	F	CLOVES	Multifocal	Superficial soft tissues	Excision	Conventional	<i>PIK3CA</i> H1047L	15
20	6-10	М		Localized	Superficial soft tissues	Excision	Conventional	<i>PIK</i> 3CA H1047R	5
21	6-10	F		Multifocal	Visceral	Excision	Kaposiform	NRAS Q61R	5
22	6-10	М		Multifocal	Superficial soft tissues	Excision	Kaposiform	NRAS Q61R	5
23	6-10	F		Multifocal	Visceral	Excision	Kaposiform	NRAS Q61R	1
24	41-45	М		Multifocal	Visceral	Core biopsy	Conventional	NRAS Q61R	6
25	6-10	F		Localized	Superficial soft tissues	Core biopsy	Kaposiform	NRAS Q61R	14
26	16-20	М		Multifocal	Superficial soft tissues	Excision	Conventional	WT	NA
27	21-25	М		Localized	Bone	Core biopsy	Conventional	WT	NA
28	0-5	М		Multifocal	Superficial soft tissues	Excision	Conventional	WT	NA
29	11-15	F		Localized	Superficial soft tissues	Excision	Conventional	WT	NA
30	6-10	F		Localized	Superficial soft tissues, bone	Biopsy	Conventional	WT	NA

146

Key: VAF - variant allele frequency of PIK3CA or NRAS; CLOVES - congenital lipomatous overgrowth, 147

vascular anomalies, epidermal nevi, and skeletal anomalies; NA - not applicable 148

149	Mutational profiling showed that these LMs had uniformly low mutational burden (median, zero
150	mutations/Mb; range, 0-2.6 mutations/Mb), and none had evidence of microsatellite instability.
151	The most common mutations were activating mutations in PIK3CA, seen in 20 (67%), and
152	activating NRAS mutations, seen in 5 (17%) (Figure 1A, B). The PIK3CA mutations included
153	both hotspot mutations in the helical domain and in the kinase domain ⁴ . The NRAS mutations all
154	altered the known hotspot at residue glutamine 61 (Q61) in the phosphorylation binding loop.
155	Of the five patients (17%) with no alterations in PIK3CA and NRAS, one case (Patient #29;
156	Table 1) had an activating GOPC-ROS1 fusion (Figure 1C) with a ROS1 missense point
157	mutation. Similar GOPC-ROS1 fusions have been reported in pediatric gliomas in the setting of
158	microdeletion of chromosome 6q22 ⁵ and, have also been found in adult lung cancer ⁶ .
159	
160	The variant allele frequencies (VAF) of the PIK3CA and NRAS mutations were relatively low
161	(median, 6%; range, 1-38%), compatible with relatively low histopathologic estimated
162	percentage of tumor nuclei (%TN) to overall cellular nuclei (median, 20%; range, 10 to 70%).

- 163 These results suggest that the *PIK3CA* and *NRAS* mutations were likely clonal, but in the
- 164 setting of relatively low tumor purity in the specimens.



165

166 **Fig. 1. Mutational Landscape and Histopathology of Lymphatic Malformations. (A)** Oncoprint

showing mutational landscape of 30 LM samples sequenced. **(B)** Lollipop plot showing spectrum of

168 *PIK3CA* and *NRAS* mutations in this cohort. (C) Schema showing details of *GOPC-ROS1* fusion identified

169 in an NRAS and PIK3CA wild-type LM. (D) Representative histologic images for LMs with conventional

and kaposiform histology. The relative frequencies of *PIK3CA* and *NRAS* mutations in the two histologic

171 variants are plotted.

173 Enrichment of *NRAS* Mutations in Lymphatic Malformations with Kaposiform Features

Histopathological analysis of the lesions by an expert dermatopathologist (J.Y.T.) identified that 174 four (13%) of the analyzed specimens had kaposiform histopathological features with highly 175 176 cellular, clustered, or sheet-like, proliferation of spindled lymphatic cells admixed with dilated thin-walled lymphatic vessels (Figure 1D). The remaining 26 lesions (87%) had conventional 177 histopathological features of classic LM, with proliferation of dilated, thin-walled lymphatic 178 179 vessels with or without luminal proteinaceous material. Lymphatic phenotype of the cells was 180 confirmed by immunopositivity for PROX1 or D2-40. Of the conventional histology LM cases (n=26), twenty (77%) had a PIK3CA mutation, while one (4%) had a NRAS mutation, and five 181 182 (19%) were wild-type for both genes, including a single-case with a GOPC-ROS1 genetic 183 fusion. Notably, all four cases of LM with kaposiform features had an activating NRAS mutation, 184 consistent with enrichment of NRAS mutation (p=0.00018) and lack of PIK3CA mutation in this histology (p=0.0046). The lone NRAS-mutant LM with conventional histology was a small core 185 needle-biopsy specimen of a large visceral tumor, raising the possibility that the histopathologic 186 187 features of the sampled tissue may not have been representative of the entire lesion due to the histologic spatial heterogeneity often seen in LMs with kaposiform histology. Additional 188 histopathologic features were assessed, including altered adipose tissue, muscularized blood 189 190 vessels, vascular endothelial cell atypia, and inflammation; no statistical significance was 191 identified between the four NRAS-mutant LM cases and the remainder of the patient cohort.

192

193 Case Report and N-of-One Clinical Trial Results

One of the conventional histology LMs was a male (age range 21-25 years) with no significant medical or family history who presented with subacute abdominal pain (Patient #9, **Table 1**). He was hospitalized and his exam revealed a distended abdomen that was tender to palpation. A computed tomography exam revealed a large solid mass based on the retroperitoneal area and

198	the pancreas (Figure 2A), and a neoplastic process was suspected. A core needle biopsy was
199	attempted but yielded no definitive tissue diagnosis. An open laparoscopic surgical biopsy was
200	performed and revealed a vascular tumor with features of a giant retroperitoneal and pancreatic
201	LM (Figure 2 D,E). After discussing a surgical approach, the patient and the surgical team
202	decided not to proceed due to the complexity of surgical resection and associated risks. The
203	tissue was submitted for NGS to identify potential biomarkers for targeted therapy.
204	
205	Clinical grade sequencing of the biopsy sample from Patient #9 uncovered a single point
206	activating mutation in PIK3CA (H1047R). All other genes in the panel were wild-type except for
207	another unit of the PI3K complex (PIK3C2B) that showed a variant (R458Q) of unknown
208	significance (VUS). To confirm activation of the PI3K α pathway, we performed
209	immunohistochemistry (IHC) staining of the downstream targets (P-AKT and P-6S), and, as
210	predicted, these phosphorylation events were detected in the lining cells of the abnormal
211	lymphatic channels (Figure 2 F,G).
212	
213	Based on the genomic profile, we designed and offered this young man a single-patient (N-of-
214	One) personalized clinical trial of the PI3K α inhibitor alpelisib (NCT03941782), which at the time
215	was still investigational (non-FDA approved). Screening procedures included an
216	echocardiogram that revealed an ejection fraction (EF) of 47%. A cardiac MRI confirmed a low
217	EF with no infiltrative process or other abnormalities. Paradoxically, the patient was completely
218	asymptomatic from a cardiac standpoint and he was able to run two miles on a daily basis. We
219	hypothesized that the decreased EF, in the absence of accompanying clinical signs or
220	symptoms of heart failure, was likely artefactual due to hemodynamic changes related to the

221 very large circulatory volume sequestration in his abdomen.





Fig. 2. Imaging and histological analysis of LM patient. (A) Baseline CT abdomen scan at the time of
 presentation demonstrating a large retroperitoneal/pancreatic LM. (B) CT abdomen scan 6 weeks after
 the initiation of alpelisib. (C) CT abdomen scan one year into the trial. (D and E) Hematoxylin and eosin
 (H&E)-stained photomicrographs of the LM showing dilated lymphatic channels percolating through
 visceral fat and associated patchy lymphocytic inflammation (4x and 10x, respectively). (F)
 Immunohistochemistry utilizing an anti-P-6S antibody demonstrates PI3Kα pathway activation within the
 channels' lining cells. (G) Anti-P-AKT positivity in the lining endothelium of lymphatic channels as well.

231	The patient was started on alpelisib daily dose of 350 mg orally ⁷ and he reported regression of
232	his abdominal bulge within a few days. He reported no adverse events and was closely
233	monitored for hyperglycemia. Repeated echocardiogram two months later showed normalization
234	of the EF. A CT scan of the abdomen done six weeks into the trial revealed remarkable
235	shrinkage of the LM (Figure 2B). Follow-up CT scans showed progressive reduction until
236	complete response at one year of trial initiation (Figure 2C). The patient continued to do well on
237	maintenance alpelisib for 2 years with no evidence of progression. After two years, alpelisib was
238	discontinued due to theoretical concerns about long-term adverse impact on vascular

239	homeostasis. Unfortunately, the mass recurred after a few weeks so the patient was resumed
240	on alpelisib with a second deep partial response, which is still ongoing for over three years.
241	
242	Alpelisib Inhibits Primary PI3K $lpha$ -mutant Lymphatic Malformation-derived Endothelial
243	Cells
244	We have also investigated the concentration-dependent effects of alpelisib on lymphatic
245	malformation-lymphatic endothelial cells (LM-LECs) isolated from a surgically resected
246	specimen ⁸ . Targeted sequencing of DNA from LM-LECs identified a somatic missense mutation
247	in PIK3CA (H1047L), the same locus altered in our alpelisib-treated patient and the site of half
248	of the PIK3CA alterations in the LM cohort studied (Table 1). In addition, a nonsense mutation
249	of the regulatory PI3K unit PIK3R3 (R309*) was also detected in the CD31-positive LM-LECs
250	and CD31-negative non-endothelial cells isolated from the same LM, indicating its germline
251	origin ⁸ . We investigated the effect of alpelisib on the growth of LM-LECs and a concentration-
252	dependent response curve was observed (Figure 3). The IC_{50} of alpelisib against LM-LECs was
253	empirically determined <i>in vitro</i> to be 4.72 x 10 ⁻⁹ M at 24 hours. This <i>in vitro</i> translational model
254	confirms the sensitivity of LM-derived human cells containing a target $H1047^{R}/L$ mutation to
255	alpelisib.



256

Figure 3. Alpelisib reduces LM-LEC viability. (A) Logarithmic dose response curve of alpelisib was performed using the xCELLigence RTCA system. 1, 3, 10, 30 and 100 nM (5 replicates/concentration) of alpelisib were used to determine the concentration-response curve. The alpelisib half maximal inhibitory concentration (IC₅₀) was calculated for LM-LEC at 24 h after treatment as 4.72 x 10⁻⁹ M. (B) Illustrative picture of LM-LEC clonogenic plaques at 24 h after alpelisib treatment (4.72 x 10⁻⁹ M). Negative, no treatment; dimethyl sulfoxide (DMSO), vehicle control. Experiments were performed two times with similar results. LM-LEC colonies were stained with crystal violet (0.3%). (C) Colony count 24 h after alpelisib

264 treatment (4.72 x 10⁻⁹ M).

265

266 Refined Genomic and Sequencing Analyses

- 267 We performed whole-genome sequencing (WGS) on paired LM/germline DNA from our index
- 268 patient to explore the mutational profile beyond the genes that were probed in the Clinical
- 269 Laboratory Improvement Amendments (CLIA)-approved clinical sequencing assay. The PIK3CA

270	H1047R mutation was identified with a Variant Allele Frequency (VAF) of 11%. This finding is
271	consistent with the \leq 10 % rate of mutant cells, and low tumor cellularity of LMs with <i>PIK3CA</i>
272	mutation ² . Few other somatic coding mutations were identified in the LM tissue
273	(Supplementary Table 1).
274	
275	To gain further molecular mechanistic insight, we have also performed RNA-seq studies to
276	identify gene expression patterns within the LM sample from our index patient. RNA-seq data of
277	biopsy samples from Patient #9 (n=2 samples; Group A) was compared to several normal

human control tissue samples from bladder, colon, kidney, and salivary gland (n=4, one sample

279 per each tissue; Group B). By using an arbitrary cut-off of at least 2-fold up or down with

adjusted *p*-values of 0.05 or less, we identified 668 up-regulated and 850 down-regulated

genes. Several of the most highly induced genes, CHI3L1, GPX1, PLIN1, PLIN4 and JAK3,

have been linked to enhanced growth or cell survival in other tumor types⁹⁻¹³. Finally, a

preliminary Gene Ontogeny (GO) analysis of Patient #9 LM revealed enrichment of mRNA of

genes involved in vascular development, cell motility, inflammatory response, positive regulation

of response to stimuli, blood vessel morphogenesis among others; notably, the kinase *JAK3*

gene was one of the highest expression mRNAs in the LMs compared to normal tissue controls

287 (data not shown).

288

289

290 DISCUSSION

Here we report the mutational landscape of a patient cohort of LMs (n=30 cases) which

underwent comprehensive genomic profiling. We have confirmed prior reports that hotspot

293 activating mutations in *PIK3CA* are common driver events in these lesions, seen in 20 (67%) of

these cases. Interestingly NRAS mutations were seen in an additional 5 (17%) cases and were

295 particularly enriched in LMs with a kaposiform histopathology. This finding suggests that LMs 296 with kaposiform features may represent a different pathologic entity ^{14,15}. As a caveat, for the one NRAS mutant LM with classic histology, the histologic classification was based on a small 297 biopsy, and it is certainly possible that kaposiform histology was present in the large visceral LM 298 299 but not captured by the limited sampling by core needle biopsy. Importantly, three of the five patients (60%) with NRAS mutant LMs had failed treatment with sirolimus prior to NGS. There 300 301 are reports that some NRAS-mutant LMs may respond to treatment with MEK inhibitors¹⁶, suggesting this may be an option for LMs with kaposiform features. 302

303

304 Of the 5 cases without either PIK3CA or NRAS mutations, all of classic histology, a single case 305 had a known pathogenic in-frame GOPC-ROS1 genetic fusion predicted to have an intact ROS1 kinase domain and thus potentially function as the driver. Similar GOPC-ROS1 fusions have 306 been seen in pediatric gliomas and adult lung cancers and may be sensitive to ROS1 307 inhibitors^{5,6}. These data suggest that most LMs may have a potentially actionable driver 308 309 mutation, with PIK3CA mutations dominating LMs with conventional histology and NRAS 310 mutations predominantly or exclusively seen in the minor subset of LMs with kaposiform 311 features. It is possible that the other NRAS and KRAS wild-type LMs may also have oncogenic 312 alterations in other members of the *PIK3CA* or MAPK signaling pathway members that were not profiled by targeted sequencing strategies. Comprehensive NGS analysis of LMs with PIK3CA 313 314 and NRAS wild-type may be required to identify any potential actionable driver mutations. In patients without solid LM tissue available for NGS, liquid biopsy--or NGS performed on 315 circulating tumor DNA (ctDNA) in peripheral blood--may be a possible solution for LMs, which 316 317 are innately associated with the vascular system and thus potentially "shedding" ctDNA into the 318 peripheral blood.

319

320 To illustrate the potential for the rapeutic intervention of the target mutations identified, we 321 performed an N-of-1 trial of alpelisib in one young adult index patient with a giant retroperitoneal and pancreatic LM with conventional histological features and a gain-of-function H1047R 322 somatic PIK3CA mutation. Our index patient experienced a rapid, complete, and durable clinical 323 response with this small molecule PI3K α inhibitor. Given the high frequency of *PIK3CA* 324 325 mutations in pediatric LMS², this finding suggests that alpelisib may be highly effective for systemic, non-surgical treatment approach to this class of disorders. Furthermore, the lack of 326 toxicity to alpelisib in our case is promising in terms of a potential future treatment of young 327 patients with LMs. Our patient did not experience increases in glucose levels, consistent with 328 329 reported lack of alpelisib-induced hyperglycemia in most pediatric patients with PROS^{17,18}. In 330 this prior series, only one patient developed new-onset hyperglycemia and this was controlled by dietary modification¹⁷. These findings suggest that the effect of alpelisib on inducing 331 332 hyperglycemia might perhaps be less of a concern in younger patients, who may have more robust glucose homeostasis, compared with older patients who may already have subclinical 333 334 insulin-resistance.

335

336 Ultimately, we decided to hold alpelisib after two years of complete radiological response, and unfortunately the LM relapsed but the patient still achieved a major partial response on the 337 second challenge with alpelisib. This result suggests that PI3K α inhibitors do not completely 338 eradicate all LM-initiating cells, and they may need to be given long-term (in our young index 339 340 patient case, perhaps over decades) in PIK3CA mutant LMs for sustained control. This class of drugs can also be envisioned to be utilized in a neoaduvant approach to render large cases 341 resectable. Our patient declined surgery after initial response and he continues on alpelisib for 342 several years. Acquired resistance mechanisms to PI3K α inhibitors have been reported, due to 343 other associated compensatory or bypassing mutations such as ones involving RAS oncogene¹⁹ 344

or *PTEN* tumor suppressor gene²⁰, and these may conceivably arise in these patients with
longer follow up over time. Deftly balancing the potential benefits of continuing treatment with
the potential for drug resistance mechanisms will require monitoring for both actionable known
and novel mutations through NGS of LM tissue samples or liquid biopsy.

349

350 In a series of pediatric patients with LMs, Luks et al. identified *PIK3CA* gene mutations in patients with sporadic LMs in 16 out of 17 patients (94%) or syndromic LMs such as the Klippel-351 Trenaunay syndrome in 19 out of 21 patients (90%), fibro-adipose vascular anomaly in 5 out of 352 8 patients (63%), along with the CLOVES syndrome in 31 out of 33 patients (94%)². H1047R 353 354 was one of the top two most frequently encountered hotspot mutations in this series. Venot et al, reported a single arm clinical trial of alpelisib in 19 patients with pediatric PROS including 355 CLOVES¹⁷. Alpelisib treatment induced clinical responses in all patients, including improvement 356 of cardiac EF as seen in our index patient. Of note, alpelisib induced responses in patients who 357 did not respond to prior treatment with mTOR inhibitors, such as rapamycin, similar to 358 observations in KRAS mutant oncology patients²¹. Small clinical series have shown that mTOR 359 inhibition can induce responses in a subset of unselected advanced LMs, with observed 360 response rates of ~50-60%²². The on driver-oncoprotein activity, higher response rates, and 361 362 tolerability suggests alpelisib may be more effective than mTOR inhibitors in this setting. It is tempting to speculate that a wide variety of *PIK3CA* mutant somatic overgrowth conditions²³ 363 may be amenable to medical treatment with FDA-approved PI3Ka inhibitors, either as neo-364 adjuvant treatment in potentially resectable cases, or as primary treatment in unresectable 365 cases^{7,20,24-26} 366

367

Furthermore, in our Whole Genome Sequencing (WGS) analysis, we identified only a few
 somatic variants within protein-coding genetic sequences (Supplementary Table 1) beyond

370 what was reported in the cancer gene panel (**Table 1**). The low frequency of somatic mutations is consistent with findings in other low-grade pediatric tumors²⁷. In addition to detecting the 371 PIK3CA H1047R mutation, this WGS confirmed the variant detected by the cancer gene panel 372 in the PIK3C2B gene and demonstrated that it was germline. Although this in PIK3C2B variant 373 374 has not been characterized and may be a benign polymorphism, this finding raises the issue of whether other alterations in the pathway may cooperate with activating mutations of PIK3CA to 375 induce cell proliferation. The low VAF driver mutations in tissue derived from LMs is likely due to 376 the fact that most pathological tissue is composed of reactive stromal elements while the clonal 377 378 cells represent a relatively small portion (presumably the lymphatic channel-lining endothelial 379 cells). Consistent with this observation, in the alpelisib-treated index patient, we observed most 380 intense activation of the PI3K α pathway in these lymphatic channel-lining endothelial cells (Figure 2 F,G). The high representations of pathways associated with vascular development, 381 cell motility, inflammatory response, positive regulation of response to stimuli, blood vessel 382 morphogenesis in our gene expression analysis is consistent with a mechanistic hypothesis that 383 384 most of the lesion represents an intense reactive response to the (presumably) clonal LM-LECs, 385 although the appropriate comparator control tissues for these lesions is not clear.

386

Evidence is accumulating that a variety of "non-malignant" syndromes associated with abnormal 387 388 tissue growth may be driven by underlying alterations in classic oncogenes²⁸. *PIK3CA* mutations are seen not only in LMs but other vascular anomalies, highlighting the role of PIK3CA 389 activation in angiogenesis, lymphangiogenesis and vascular neoplasms^{29-31 32}. Endometriosis, 390 391 uterine fibroids and seborrheic keratoses all have been found to harbor mutations in cancer 392 related genes³³⁻³⁷. These findings suggest that targeted therapies being developed for invasive cancers may also be active in proliferative lesions that are not classified as invasive cancers 393 that harbor the targeted alteration. 394

395

396	In summary (Figure 4), we find that the majority of LMs have driver mutations that are
397	potentially targetable. LMs with classic histology mostly have PIK3CA mutations that may
398	respond to alpelisib. LMs with kaposiform histopathology are enriched in NRAS mutations, and
399	studies are required to determine if these may respond to clinically available MEK inhibitors.
400	LMs that are wild-type for PIK3CA and NRAS may have other actionable alterations, such as
401	the GOPC-ROS1 fusion seen in our series and may require more comprehensive genomic
402	analyses to identify them. Systemic treatment with targeted therapy aimed at the driver mutation
403	in LMs may be an option for some patients who are not controlled by surgery and other
404	conventional treatments.





406 Figure 4. Graphical summary of the mutations found in genomic analysis of LM patient cohort

407 (Created with BioRender.com). (A) The majority of LMs have driver mutations that are potentially

targetable. (B) LMs with NRAS mutations had kaposiform histopathology. (C) An N-of-1 clinical trial is

409 reported in a patient with a targetable PIK3CA mutation. (D) Comprehensive genomic analyses may

410 reveal further actionable molecular insights.

411 **METHODS**

412	Genomics and DNA Sequencing. Hybrid-capture DNA sequencing targeting exons of at least
413	324 cancer genes and select introns of 36 genes were performed on the patient samples; a
414	subset (n=2) were also analyzed with plus RNA sequencing of 265 genes to improve
415	rearrangement detection. A total of 30 patient samples were sequenced with either the DNA-
416	only assay (n=28; Foundation One CDx, Foundation Medicine; Cambridge, MA) or the
417	DNA+RNA assay (n=2; Foundation One Heme, Foundation Medicine; Cambridge, MA).
418	
419	Immunohistochemistry. Immunohistochemistry (IHC) was performed on formalin-fixed,
420	deparaffinized, 5-micron thick sections mounted on charged slides. Antibodies to P-AKT
421	(Ser473), and P-6S (Ser240/Ser244) were obtained from Cell Signaling Technology, Danvers,
422	Massachusetts. Diaminobenzidine (DAB) was used as the chromogen and hematoxylin as the
423	counterstain. All stages of staining were carried out on an automated system (Ventana
424	Discovery Research Instrument; Ventana, Tucson, Arizona). Positive and negative controls
425	were appropriately reactive. A surgical pathologist with subspecialty interest in musculoskeletal
426	pathology (T.J.B.) interpreted the results.

427

LM-LEC Sensitivity to Alpelisib In Vitro. LM-LEC cells were maintained as described ⁸ and negative for mycoplasma at the time of these studies. Mycoplasma test was performed using the MycoAlert Mycoplasma Detection Kit (Cat # LT07-218, Lonza) following the manufacturer's instructions. Real-time analysis of cell viability was performed by using the xCELLigence system RTCA SP (ACEA Biosciences). Briefly, 5x10³ LM-LECs per well were seeded in an E-Plate 96 (ACEA Biosciences) and cell proliferation was recorded hourly. When the cells reached the exponential growth phase, new media containing alpelisib at 1, 3, 10, 30, or 100 nM was added

and alpelisib cytotoxic effect was recorded hourly. IC₅₀ was calculated by using the DoseResponse Curve (DRC) function available in the xCELLigence software Version 2.0. Cell index
(%) reflects cell viability.

438

439 *Clonogenic Survival Assays*. For the clonogenic survival assay, the LM-LEC were trypsinized, 440 counted and plated in complete growth media on 6-well plates (Falcon) (400 cells/well). Seven 441 days later, alpelisib (at the empirically determined IC_{50} from a standard calibration curve) was 442 added in duplicate wells. After 24 h or 48 h of incubation, cells were fixed and stained in 50% 443 methanol in water containing 0.3% crystal violet to facilitate counting of colonies (≥50 cells).

444

Statistics. All values are expressed as mean with error bars expressed as SD. For comparison between untreated (negative), DMSO control, and Alpelisib treated LM-LEC cells, the ordinary one-way ANOVA and Tukey's multiple comparisons test with a single pooled variance were used. Statistical analysis was performed using the Graph Pad Prism 7.0d software (GraphPad Software Inc., San Diego, CA, USA). Fisher's exact test was used for categorical data, owing to the sizes of the cohorts. A two-tailed P value of <0.05 was considered to be statistically significant.

452

Study approval. Approval for this study, including a waiver of informed consent and Health Insurance Portability and Accountability Act waiver of authorization, was obtained from the Western Institutional Review Board (IRB; protocol #20152817). A single-institution personalized clinical protocol to treat the patient with the experimental PI3Kα inhibitor alpelisib was scientifically reviewed by the Protocol Review and Monitoring Committee (PRMC) and approved by the local Institutional Review Board (IRB) of the University of New Mexico Comprehensive

- 459 Cancer Center. The study (NCT03941782) was conducted in accordance with the protocol,
- 460 Good Clinical Practice guidelines, and the provisions of the Declaration of Helsinki. CARE
- 461 reporting guidelines were also used for this patient³⁸. The index patient signed an informed
- 462 written consent form.

464	Author contributions: Conceptualization: MFS, JYT, ESS, MM, RP, SG, WA; Methodology:
465	MFS, JYT, ESS, PB, IR, CAT, ASD, TLS, TJB, BKM, RNG, JEB, SAN, GMR, RG; Investigation:
466	MFS, JYT, ESS, PB, IR, CAT, ASD, TLS, TJB, BKM, RNG, JEB, SAN, GMR, RG; Visualization:
467	MFS, JYT, ESS, PB, IR, CAT, ASD, TLS, TJB, BKM, RNG, JEB, SAN, GMR, RG; Funding
468	acquisition: MFS, MM, RP, SG, WA; Project administration: MFS, JYT, RP, SG, WA;
469	Supervision: MFS, JYT, RP, SG, WA; Writing – original draft: MFS, JYT, ESS, RP, SG, WA;
470	Writing – review & editing: MFS, JYT, ESS, MM, PB, IR, CAT, ASD, TLS, TJB, BKM, RNG,
471	JEB, SAN, GMR, RG, RP, SG, WA
472	
473	Acknowledgments: We thank Dr. Kathryn J. Brayer for technical assistance and Dr. Helen
474	Pickersgill (Life Science Editors) for professional manuscript editing services.
475	
476	Funding: R.P. and W.A. are supported by awards from the Levy-Longenbaugh Fund. S.G. is
477	supported by awards from the Hugs for Brady Foundation. This work has been funded in part by
478	the NCI Cancer Center Support Grants (CCSG; P30) to the University of Arizona Cancer Center
479	(CA023074), the University of New Mexico Comprehensive Cancer Center (CA118100), and the
480	Rutgers Cancer Institute of New Jersey (CA072720). B.K.M. was supported by National Science
481	Foundation via Graduate Research Fellowship DGE-1143953.
482	
483	

485 **References**

- 4861.Perkins JA, Manning SC, Tempero RM, Cunningham MJ, Edmonds JL, Jr., Hoffer FA,487Egbert MA. Lymphatic malformations: review of current treatment. Otolaryngol Head488Neck Surg. 2010;142(6):795-803, 803 e791. doi: 10.1016/j.otohns.2010.02.026
- Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV, Rialon KL, Guevara CJ,
 Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, Maclellan RA, Mulliken JB,
 Rahbar R, Spencer SA, Trenor CC, 3rd, Upton J, Zurakowski D, Perkins JA, Kirsh A,
 Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA, Murillo R. Lymphatic
 and other vascular malformative/overgrowth disorders are caused by somatic mutations
 in PIK3CA. *J Pediatr.* 2015;166(4):1048-1054 e1041-1045. doi:
 10.1016/j.jpeds.2014.12.069
- Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K
 Pathway in Human Disease. *Cell.* 2017;170(4):605-635. doi: 10.1016/j.cell.2017.07.029
- 498
 4. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell
 499
 500
 500
 501
 501
 502
 503
 504
 504
 505
 505
 506
 507
 508
 508
 509
 509
 509
 500
 500
 500
 500
 500
 500
 501
 501
 501
 502
 503
 504
 504
 505
 505
 504
 505
 505
 505
 506
 507
 507
 508
 508
 509
 509
 509
 500
 500
 500
 500
 500
 500
 501
 501
 501
 501
 502
 501
 502
 501
 502
 501
 502
 501
 501
 502
 501
 501
 501
 502
 501
 502
 501
 502
 501
 502
 501
 502
 501
 502
 501
 502
 501
 502
 501
 502
 502
 503
 504
 504
 504
 504
 505
 504
 505
 504
 504
 505
 504
 504
 504
 505
 504
 504
 504
 504
 504
 504
 505
 504
 504
 505
 504
 504
- 5. Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, Woltjer R, Somwar
 R, Gilheeney SW, DeCarvalo A, Mikkelson T, Van Meir EG, Ladanyi M, Druker BJ. Rare
 but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are
 Targetable Oncogenes in Glioma. *Clin Cancer Res.* 2018;24(24):6471-6482. doi:
 10.1158/1078-0432.CCR-18-1052
- 5076.Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent508cancers biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35-55.509doi: 10.1038/s41571-020-0408-9
- Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR,
 Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D,
 Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Phosphatidylinositol 3 Kinase alpha-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid
 Tumors: Results From the First-in-Human Study. *J Clin Oncol.* 2018;36(13):1291-1299.
 doi: 10.1200/JCO.2017.72.7107
- 5168.Boscolo E, Coma S, Luks VL, Greene AK, Klagsbrun M, Warman ML, Bischoff J. AKT517hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells518from a patient with lymphatic malformation. Angiogenesis. 2015;18(2):151-162. doi:51910.1007/s10456-014-9453-2
- 5209.Cheng Y, Xu T, Li S, Ruan H. GPX1, a biomarker for the diagnosis and prognosis of
kidney cancer, promotes the progression of kidney cancer. Aging (Albany NY).5222019;11(24):12165-12176. doi: 10.18632/aging.102555
- 52310.Qiu QC, Wang L, Jin SS, Liu GF, Liu J, Ma L, Mao RF, Ma YY, Zhao N, Chen M, Lin BY.524524CHI3L1 promotes tumor progression by activating TGF-beta signaling pathway in525hepatocellular carcinoma. Sci Rep. 2018;8(1):15029. doi: 10.1038/s41598-018-33239-8

- Sirois I. Aquilar-Mahecha A. Lafleur J. Fowler E. Vu V. Scriver M. Buchanan M. Chabot 526 11. C, Ramanathan A, Balachandran B, Legare S, Przybytkowski E, Lan C, Krzemien U, 527 Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-528 529 Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, 530 Mihalcioiu C, Majewski J, Basik M. A Unique Morphological Phenotype in 531 Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and 532 PLIN4 Expression as a Molecular Vulnerability. Mol Cancer Res. 2019;17(12):2492-533 534 2507. doi: 10.1158/1541-7786.MCR-19-0264
- Vadivel CK, Gluud M, Torres-Rusillo S, Boding L, Willerslev-Olsen A, Buus TB, Nielsen TK, Persson JL, Bonefeld CM, Geisler C, Krejsgaard T, Fuglsang AT, Odum N,
 Woetmann A. JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL). *Cancers (Basel)*. 2021;13(2). doi: 10.3390/cancers13020280
- 13. Zhang Q, Zhang P, Li B, Dang H, Jiang J, Meng L, Zhang H, Zhang Y, Wang X, Li Q,
 Wang Y, Liu C, Li F. The Expression of Perilipin Family Proteins can be used as
 Diagnostic Markers of Liposarcoma and to Differentiate Subtypes. *J Cancer.*2020;11(14):4081-4090. doi: 10.7150/jca.41736
- Barclay SF, Inman KW, Luks VL, McIntyre JB, Al-Ibraheemi A, Church AJ, Perez-Atayde
 AR, Mangray S, Jeng M, Kreimer SR, Walker L, Fishman SJ, Alomari AI, Chaudry G,
 Trenor Iii CC, Adams D, Kozakewich HPW, Kurek KC. A somatic activating NRAS
 variant associated with kaposiform lymphangiomatosis. *Genet Med.* 2019;21(7):15171524. doi: 10.1038/s41436-018-0390-0
- 54815.Croteau SE, Kozakewich HP, Perez-Atayde AR, Fishman SJ, Alomari AI, Chaudry G,549Mulliken JB, Trenor CC, 3rd. Kaposiform lymphangiomatosis: a distinct aggressive550lymphatic anomaly. J Pediatr. 2014;164(2):383-388. doi: 10.1016/j.jpeds.2013.10.013
- 16. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM,
 Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C,
 Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V,
 Bozon V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with
 advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised,
 phase 3 trial. *Lancet Oncol.* 2017;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8
- Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C, Boccara O, Sarnacki S, Boddaert N, Pannier S, Martinez F, Magassa S, Yamaguchi J, Knebelmann B, Merville P, Grenier N, Joly D, Cormier-Daire V, Michot C, Bole-Feysot C, Picard A, Soupre V, Lyonnet S, Sadoine J, Slimani L, Chaussain C, Laroche-Raynaud C, Guibaud L, Broissand C, Amiel J, Legendre C, Terzi F, Canaud G. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. *Nature*. 2018;558(7711):540-546. doi: 10.1038/s41586-018-0217-9
- Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D,
 Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL. A Phase Ib Study
 of Alpelisib (BYL719), a PI3Kalpha-Specific Inhibitor, with Letrozole in ER+/HER2Metastatic Breast Cancer. *Clin Cancer Res.* 2017;23(1):26-34. doi: 10.1158/10780432.CCR-16-0134

- Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM,
 Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ,
 Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR
 inhibitors. *Cell Rep.* 2014;6(2):377-387. doi: 10.1016/j.celrep.2013.12.035
- Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage
 HM, Sampath D, Salphati L, Lin RS, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J.
 Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with
 Advanced Solid Tumors. *Cancer Discov.* 2017;7(7):704-715. doi: 10.1158/21598290.CD-16-1080
- Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M,
 Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini
 M, Baselga J, Gallicchio M, Biffo S, Bardelli A. Deregulation of the PI3K and KRAS
 signaling pathways in human cancer cells determines their response to everolimus. J
 Clin Invest. 2010;120(8):2858-2866. doi: 10.1172/JCI37539
- Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, Costa J, Ferreira J.
 Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic
 review. J Vasc Surg. 2020;71(1):318-327. doi: 10.1016/j.jvs.2019.06.217
- Hucthagowder V, Shenoy A, Corliss M, Vigh-Conrad KA, Storer C, Grange DK, Cottrell
 CE. Utility of clinical high-depth next generation sequencing for somatic variant detection
 in the PIK3CA-related overgrowth spectrum. *Clin Genet.* 2017;91(1):79-85. doi:
 10.1111/cge.12819
- Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck
 SS, Ru QC, Peters M, Goldbrunner M, Baselga J. Phase I, dose-escalation study of
 BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J *Clin Oncol.* 2012;30(3):282-290. doi: 10.1200/JCO.2011.36.1360
- Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo
 AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno
 A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase
 inhibitor, in patients with advanced solid tumors. *Clin Cancer Res.* 2012;18(15):41734182. doi: 10.1158/1078-0432.CCR-12-0714
- Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ,
 Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A,
 Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis
 ER, Berger MF, Baselga J, Scaltriti M. Convergent loss of PTEN leads to clinical
 resistance to a PI(3)Kalpha inhibitor. *Nature*. 2015;518(7538):240-244. doi:
 10.1038/nature13948
- Akhavanfard S, Padmanabhan R, Yehia L, Cheng F, Eng C. Comprehensive germline
 genomic profiles of children, adolescents and young adults with solid tumors. *Nat Commun.* 2020;11(1):2206. doi: 10.1038/s41467-020-16067-1
- 608
 28.
 Mustjoki S, Young NS. Somatic Mutations in "Benign" Disease. N Engl J Med.

 609
 2021;384(21):2039-2052. doi: 10.1056/NEJMra2101920

- Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, Bague S,
 Scaltriti M, Antonescu CR, Baselga E, Baselga J. Somatic PIK3CA mutations as a driver
 of sporadic venous malformations. *Sci Transl Med.* 2016;8(332):332ra342. doi:
 10.1126/scitranslmed.aaf1164
- 61430.Castillo SD, Tzouanacou E, Zaw-Thin M, Berenjeno IM, Parker VE, Chivite I, Mila-615Guasch M, Pearce W, Solomon I, Angulo-Urarte A, Figueiredo AM, Dewhurst RE, Knox616RG, Clark GR, Scudamore CL, Badar A, Kalber TL, Foster J, Stuckey DJ, David AL,617Phillips WA, Lythgoe MF, Wilson V, Semple RK, Sebire NJ, Kinsler VA, Graupera M,618Vanhaesebroeck B. Somatic activating mutations in Pik3ca cause sporadic venous619malformations in mice and humans. Sci Transl Med. 2016;8(332):332ra343. doi:62010.1126/scitranslmed.aad9982
- Limaye N, Kangas J, Mendola A, Godfraind C, Schlogel MJ, Helaers R, Eklund L, Boon
 LM, Vikkula M. Somatic Activating PIK3CA Mutations Cause Venous Malformation. *Am J Hum Genet.* 2015;97(6):914-921. doi: 10.1016/j.ajhg.2015.11.011
- Ren AA, Snellings DA, Su YS, Hong CC, Castro M, Tang AT, Detter MR, Hobson N,
 Girard R, Romanos S, Lightle R, Moore T, Shenkar R, Benavides C, Beaman MM,
 Müller-Fielitz H, Chen M, Mericko P, Yang J, Sung DC, Lawton MT, Ruppert JM,
 Schwaninger M, Körbelin J, Potente M, Awad IA, Marchuk DA, Kahn ML. PIK3CA and
 CCM mutations fuel cavernomas through a cancer-like mechanism. *Nature*. 2021. doi:
 10.1038/s41586-021-03562-8
- 33. Rafnar T, Gunnarsson B, Stefansson OA, Sulem P, Ingason A, Frigge ML, Stefansdottir 630 L, Sigurdsson JK, Tragante V, Steinthorsdottir V, Styrkarsdottir U, Stacey SN, 631 632 Gudmundsson J, Arnadottir GA, Oddsson A, Zink F, Halldorsson G, Sveinbjornsson G, Kristjansson RP, Davidsson OB, Salvarsdottir A, Thoroddsen A, Helgadottir EA, 633 Kristjansdottir K, Ingthorsson O, Gudmundsson V, Geirsson RT, Arnadottir R, 634 Gudbjartsson DF, Masson G, Asselbergs FW, Jonasson JG, Olafsson K, 635 636 Thorsteinsdottir U, Halldorsson BV, Thorleifsson G, Stefansson K. Variants associating with uterine leiomyoma highlight genetic background shared by various cancers and 637 hormone-related traits. Nat Commun. 2018;9(1):3636. doi: 10.1038/s41467-018-05428-6 638
- 639 34. Gallagher CS, Makinen N, Harris HR, Rahmioglu N, Uimari O, Cook JP, Shigesi N, Ferreira T. Velez-Edwards DR, Edwards TL, Mortlock S, Ruhioglu Z, Day F, Becker CM, 640 Karhunen V. Martikainen H. Jarvelin MR, Cantor RM, Ridker PM, Terry KL, Buring JE, 641 642 Gordon SD, Medland SE, Montgomery GW, Nyholt DR, Hinds DA, Tung JY, and Me Research T, Perry JRB, Lind PA, Painter JN, Martin NG, Morris AP, Chasman DI, 643 Missmer SA, Zondervan KT, Morton CC. Genome-wide association and epidemiological 644 analyses reveal common genetic origins between uterine leiomyomata and 645 endometriosis. Nat Commun. 2019;10(1):4857. doi: 10.1038/s41467-019-12536-4 646
- Fritsche LG, Gruber SB, Wu Z, Schmidt EM, Zawistowski M, Moser SE, Blanc VM,
 Brummett CM, Kheterpal S, Abecasis GR, Mukherjee B. Association of Polygenic Risk
 Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan
 Genomics Initiative. *Am J Hum Genet.* 2018;102(6):1048-1061. doi:
 10.1016/j.ajhg.2018.04.001
- 36. Sanders MGH, Pardo LM, Uitterlinden AG, Smith AM, Ginger RS, Nijsten T. The
 Genetics of Seborrheic Dermatitis: A Candidate Gene Approach and Pilot Genome-Wide

- 654Association Study. J Invest Dermatol. 2018;138(4):991-993. doi:65510.1016/j.jid.2017.11.020
- Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noe M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM. Cancer-Associated Mutations in Endometriosis without Cancer. *N Engl J Med.* 2017;376(19):1835-1848. doi: 10.1056/NEJMoa1614814
- 38. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, Group C. The CARE
 guidelines: consensus-based clinical case reporting guideline development. *BMJ Case Rep.* 2013;2013. doi: 10.1136/bcr-2013-201554

666

Gene_Name	Protein_Change	VAF	alt_depth	ref_depth	COSMIC
HRNR 0.105	p.T616A	0.105	4	51	
OR2T3	p.S247F	0.171	8	53	
PLXDC2	p.V396I	0.167	4	22	
FOLH1	p.R190W	0.333	8	20	
IPO8	p.M488fs	0.125	3	28	
KRR1	p.R134Q	0.188	3	17	
KRTAP4-11	p.L161V	0.116	9	49	
TTYH1	p.E440fs	0.130	6	31	
TTYH1	p.440_441insH	0.130	6	30	
KIF5C	p.K151fs	0.200	3	16	
LY75-CD302	p.T1393I	0.188	3	18	
BARD1	p.P24S	0.087	4	59	
KRTAP10-12	p.P92S	0.133	5	38	
NFXL1	p.P246L	0.176	3	20	
PLA2G7	p.R92H	0.188	3	18	
NAT2	p.R268K	0.200	7	28	p.R268K
AQP7	p.Y64F	0.068	7	88	
KIAA1984	p.N421T	0.125	4	42	

Supplementary Table 1. Somatic coding mutations identified from whole genome 668 sequencing 669

670 671

The genetic coding variants that exist in LM but do not exist in germline DNA. These pass MuTect2 quality

filters (designed to call somatic variants only) and have three or more alternate reads. VAF, Variant Allele 672

Frequency; COSMIC, Catalogue Of Somatic Mutations In Cancer. 673